首页> 外文期刊>Movement disorders >International Cooperative Ataxia Rating Scale (ICARS): appropriate for studies of Friedreich's ataxia?
【24h】

International Cooperative Ataxia Rating Scale (ICARS): appropriate for studies of Friedreich's ataxia?

机译:国际合作性共济失调评定量表(ICARS):是否适合研究Friedreich的共济失调?

获取原文
获取原文并翻译 | 示例
           

摘要

Clinicians require scientifically rigorous, clinically meaningful rating scales to evaluate the health impact of disease and treatment that cannot be measured using conventional laboratory instruments. This study evaluated the psychometric properties of the International Cooperative Ataxia Rating Scale (ICARS), a commonly used clinician-rated measure, in Friedreich's ataxia (FRDA). People with confirmed FRDA were assessed by using the ICARS. Two assumptions of its measurement model were tested: the legitimacy of reporting ICARS scores in FRDA, and the acceptability, reliability, and validity of total and subscale scores. Seventy-seven people with FRDA were assessed. The ICARS total score effectively satisfied all psychometric criteria tested. The posture and gait disturbances subscale also performed well. The other three subscales did not pass standard criteria for tests of scaling assumptions, reliability, and validity. This small study recommends only the use of the ICARS total score as a measure of FRDA. However, the extent to which this score quantifies the true extent of FRDA remains uncertain as our validity testing was limited, partly by the lack of appropriate validating measures. Further validity testing, and examination of responsiveness, is required before the ICARS can be recommended as an outcome measure for treatment trials of FDRA.
机译:临床医生需要科学严谨,具有临床意义的评级量表来评估疾病和治疗对健康的影响,而这是使用常规实验室仪器无法衡量的。这项研究评估了国际合作性共济失调评定量表(ICARS)的心理计量学特性,该量表是弗里德里希共济失调(FRDA)常用的临床医生评定量度。确诊为FRDA的人群通过ICARS进行评估。测试了其测量模型的两个假设:在FRDA中报告ICARS分数的合法性,以及总分和分量表分数的可接受性,可靠性和有效性。评估了FRDA的77人。 ICARS总分有效地满足了所有测验的心理测验标准。姿势和步态干扰分量表也表现良好。其他三个子量表未通过有关衡量假设,可靠性和有效性的标准标准。这项小型研究仅建议使用ICARS总分来衡量FRDA。然而,由于我们的有效性测试受到限制,部分原因是缺乏适当的验证措施,因此该分数量化FRDA真实范围的程度仍不确定。在推荐ICARS作为FDRA治疗试验的结局指标之前,需要进一步的有效性测试和反应性检查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号